190P - Measurement of molecular biomarkers to predict tumor response in estrogen receptor positive breast cancer after dose-dense (biweekly) paclitaxel/ca...

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer, Early Stage
Biomarkers
Presenter Kun Wang
Citation Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364
Authors K. Wang1, T. Zhu2, C. Yang2, Y. Zhang2, L. Zhang2
  • 1The Second Department Of Breast Cancer, Guangdong General Hospital, 510000 - Guangzhou/CN
  • 2The Second Department Of Breast Cancer, Guangdong General Hospital, 510120 - Guangzhou/CN

Abstract

Background

Dose-dense (biweekly) paclitaxel/carboplatin(PC) as neoadjuvant Chemotherapy (NCT) for operable breast cancer is feasible and efficient. This study was to analysis the relationship between the molecular biomarkers and tumor response in estrogen receptor(ER) positive breast cancer.

Methods

84 ER-positive breast cancer patients treated with Dose-dense (biweekly) paclitaxel/carboplatin NCT were analyzed for expression of progesrone receptor (PgR), Tau, ki67, HER2, Bcl-2 by immunohistochemistry (IHC), these data were used to test whether these biomarkers can predict tumor response. The primary endpoint was a pathologically complete response (pCR). The second endpoint was the change in tumor size between pre and post NCT.

Results

Univariate analysis showed that HER2 positive (53.85% vs 8.62%, p 

Conclusions

This study investigates the value of traditional biological markers, Bcl-2 and Tau in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.

Clinical trial identification

NCT02059876

Legal entity responsible for the study

N/A

Funding

Guangdong General Hospital

Disclosure

All authors have declared no conflicts of interest.